CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced updates to its development program for IPI-926, including that the company has completed enrollment of its Phase 2 trial of IPI-926 in patients with previously untreated pancreatic cancer. The double-blind, placebo-controlled trial of 122 randomized patients is designed to compare IPI-926 in combination with gemcitabine (also known as Gemzar®) to treatment with placebo and gemcitabine. The primary endpoint of the trial is overall survival. Infinity initiated this Phase 2 trial in February 2011.
